Real-time continuous glucose monitoring in randomized control trials.
Several recent randomized controlled trials offer firm evidence supporting the efficacy and safety of real-time continuous glucose monitoring (RT-CGM) in type 1 diabetes mellitus (T1DM). Improved metabolic control with significant lowering of glycated hemoglobin (A1C) along with other parameters of glycemia, and without a concomitant increase in hypoglycemia, has been demonstrated. However, poor compliance in adolescents has been a limiting factor in that age group. The potential of RT-CGM of reducing hypoglycemia in well-controlled individuals with T1DM is anticipated but remains to be confirmed. The current high cost of this technology may limit clinical experience in routine clinical settings.